Correct Answer: D. Hydration
This clinical presentation is classic for tumor lysis syndrome (TLS), a life-threatening oncologic emergency that occurs when chemotherapy rapidly destroys malignant cells, releasing intracellular contents (potassium, phosphate, uric acid, nucleic acids) into the bloodstream. The boy's constellation of findings—hyperuricemia, hyperkalemia, raised creatinine (indicating acute kidney injury), oliguria, and periorbital puffiness (fluid overload/edema)—confirms TLS with acute renal failure.
The next best step in acute TLS management is aggressive intravenous hydration with normal saline (0.9% NaCl) at 2–3 L/m²/day or higher, aiming for urine output of 200–300 mL/m²/hour. Hydration is the cornerstone because it: (1) dilutes serum uric acid and other electrolytes, reducing precipitation in renal tubules; (2) increases glomerular filtration rate and urine flow, promoting renal excretion of uric acid and potassium; (3) prevents acute tubular necrosis and preserves renal function. Hydration must be initiated before or immediately upon starting chemotherapy in high-risk patients and is the first-line intervention even in established TLS. Urate-lowering agents (rasburicase, allopurinol) and other interventions are adjunctive and come after hydration is established. Per Indian pediatric guidelines and Harrison's, hydration is the foundational pillar of TLS prevention and acute management.
Why the other options are wrong
A. Rasburicase — Rasburicase is a recombinant urate oxidase that rapidly converts uric acid to allantoin (5–10 times more soluble), making it highly effective for hyperuricemia in TLS. However, it is not the first step—it is an adjunctive agent used after hydration is established. Rasburicase is also expensive, not universally available in Indian settings, and reserved for high-risk or established hyperuricemia. The question asks for the 'next best step,' and hydration must precede or accompany urate-lowering therapy. B. Allopurinol — Allopurinol inhibits xanthine oxidase, reducing uric acid production. While it is the standard urate-lowering agent in India (cheaper, widely available), it is slower-acting (takes 24–48 hours to reduce uric acid levels) and does not address the immediate hyperkalemia or fluid overload. Allopurinol is used for prevention of TLS in high-risk patients before chemotherapy, not as the acute management step. In acute TLS with established hyperuricemia and renal failure, hydration and rasburicase (if available) take priority. C. Probenecid — Probenecid is a uricosuric agent that increases renal excretion of uric acid by inhibiting tubular reabsorption. However, it is contraindicated in acute TLS because it requires adequate glomerular filtration and urine flow to be effective—both of which are already compromised in this boy (oliguria, raised creatinine). Probenecid may precipitate uric acid crystals in acidic urine and worsen acute kidney injury. It has no role in acute TLS management.
High-Yield Facts
- Tumor lysis syndrome occurs within 12–72 hours of chemotherapy initiation in rapidly dividing malignancies (lymphomas, leukemias, Wilms tumor); characterized by hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia.
- Aggressive IV hydration (0.9% NaCl, 2–3 L/m²/day, target urine output 200–300 mL/m²/hour) is the first-line and most critical intervention in TLS, preventing acute tubular necrosis and preserving renal function.
- Rasburicase (recombinant urate oxidase) is the preferred urate-lowering agent in acute TLS if available; allopurinol is slower and used for prevention; probenecid is contraindicated in oliguria.
- Periorbital puffiness and oliguria in TLS reflect acute kidney injury from uric acid crystal precipitation in renal tubules and hyperkalemia-induced cardiac/renal dysfunction.
- Alkalinization of urine (sodium bicarbonate, target pH >6.5) was historically used but is now de-emphasized because it may precipitate calcium phosphate; hydration alone is preferred.
Mnemonics
TLS Management: HUP Hydration (first), Urate-lowering agents (rasburicase/allopurinol), Potassium management (insulin-glucose, calcium gluconate, diuretics). Hydration is always step 1. When to use Rasburicase vs Allopurinol Rasburicase = acute TLS, fast-acting, expensive. Allopurinol = prevention before chemo, slow-acting, cheap. In India, allopurinol is standard prophylaxis; rasburicase reserved for acute/severe cases.
NBE Trap
NBE pairs 'hyperuricemia' with 'urate-lowering agents' to lure students into choosing rasburicase or allopurinol without recognizing that hydration is the foundational first step that must be initiated before or alongside any urate-lowering therapy. The trap exploits the assumption that the most specific drug for the biochemical abnormality is the answer.
Clinical Pearl
In Indian pediatric oncology centers, TLS is a leading cause of preventable death in newly diagnosed leukemia and lymphoma. The mantra is: "Hydrate before you radiate (or chemicate)"—aggressive IV fluids started before chemotherapy in high-risk patients can prevent TLS entirely. Once TLS is established, hydration remains the cornerstone while awaiting urate-lowering agents to take effect.
_Reference: Harrison Ch. 104 (Oncologic Emergencies); OP Ghai Ch. 8 (Fluid & Electrolyte Management); Robbins Ch. 7 (Acute Kidney Injury)_